Antisense News and Research

RSS

Antisense is the non-coding strand in double-stranded DNA. The antisense strand serves as the template for mRNA synthesis.

A paper-based sensor for detecting COVID-19

News-Medical talks to Dipanjan Pan about the development of a paper-based electrochemical sensor that can detect COVID-19 in less than five minutes.

5 Jan 2021

FDA takes first steps in bringing clarity to emerging area of individualized drug development

Advances in scientific knowledge and drug development technology have provided an opportunity for new approaches to drug development, including the development of drugs for the treatment of rare diseases.

4 Jan 2021

Gene-regulating snippet of RNA may contribute to breast cancer metastasis

Cold Spring Harbor Laboratory (CSHL) scientists have discovered a gene-regulating snippet of RNA that may contribute to the spread of many breast cancers.

22 Dec 2020

Paper-based electrochemical sensor can enable rapid detection of SARS-CoV-2

As the COVID-19 pandemic continues to spread across the world, testing remains a key strategy for tracking and containing the virus.

7 Dec 2020

Adding exercise to genetic treatment reverses fatigue in mice with common myotonic dystrophy

Adding exercise to a genetic treatment for myotonic dystrophy type 1 (DM1) was more effective at reversing fatigue than administering the treatment alone in a study using a mouse model of the disease.

30 Nov 2020

Peptide-conjugated morpholino oligomers effectively inhibit SARS-CoV-2 in vero cells

The hunt for antivirals has reached an unprecedented pace in light of the coronavirus 2019 (COVID-19) pandemic. The causal agent for this disease – severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – has already infected over 52 million people worldwide, and has subsequently claimed over 1.3 million lives. However, among the innumerable promising drug candidates that help battle the virus and mitigate its damage, none have yet made it to the clinic.

12 Nov 2020

SARS-CoV-2 RNA genome structure reveals potential targets for development of drugs

The SARS-CoV-2 coronavirus RNA genome structure was studied in detail by researchers from the University of Groningen, the International Institute of Molecular and Cell Biology in Warsaw, and Leiden University.

10 Nov 2020

RNA-binding proteins may suppress antiviral defenses against SARS-CoV-2

Conducted by researchers in South Korea at the Institute for Basic Science and the International Vaccine Institute, a new study published on the preprint server bioRxiv in November 2020 describes the many host proteins that bind with the ribonucleic acid (RNA) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and regulate the replication of the virus.

4 Nov 2020

Research projects receive BTCA grants to develop novel drugs for various diseases

Five research projects with exceptional promise to deliver new life-changing and health-altering therapies have received the inaugural Blavatnik Therapeutics Challenge Awards (BTCA) at Harvard Medical School.

30 Oct 2020

Inhibition of SARS-CoV-2 with antisense oligonucleotides

A part of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral RNA is highly conserved. Researchers have used this as a target for designing antisense oligonucleotide gapmers to cleave the RNA and disrupt virus replication. Their research is published as a preprint on the online server bioRxiv in September 2020.

22 Sep 2020

Research underlines SARS-CoV-2 N-terminal domain of Nsp1 as a potential drug target

A recent study reveals how the non-structural protein 1 (NSP1) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) plays a crucial role in inhibiting the host cell protein synthesis but simultaneously facilitating the viral protein synthesis.

21 Sep 2020

Investigational drug may reduce protein buildup and neurological decline linked to ALS, FTD

An investigational drug that targets an instigator of the TDP-43 protein, a well-known hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), may reduce the protein's buildup and neurological decline associated with these disorders, suggests a pre-clinical study from researchers at Penn Medicine and Mayo Clinic.

8 Sep 2020

Evidence of SARS-CoV-2 coronavirus particles in heart tissue

Researchers in Milan, Italy, have identified the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the heart tissue of deceased coronavirus disease 2019 (COVID-19) patients who had died from respiratory failure, without showing any signs of cardiac involvement.

27 Aug 2020

Faulty RNA quality control system leads to haywire production of toxic proteins in FTLD/ALS

Researchers at Osaka University identify vicious cycle involving RNA exosome that accelerates disease progression in FTLD/ALS

24 Aug 2020

Researchers identify new mechanism that causes leukemia

Every year, 1.1 million new cases of blood cancers are diagnosed worldwide. Presently, chemotherapy remains the most common and effective course of treatment.

13 Aug 2020

FDA approves new treatment option for patients with rare Duchenne muscular dystrophy mutation

Today, the U.S. Food and Drug Administration granted accelerated approval to Viltepso (viltolarsen) injection for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.

12 Aug 2020

Large-scale analysis of Alport syndrome reveals the effectiveness of existing treatments

A large-scale analysis of the clinical characteristics of Alport syndrome in Japanese patients has revealed that the effectiveness of existing treatment with ACE inhibitors and/or angiotensin receptor blockers (RAS inhibitors) varies depending on the type of mutation in the syndrome's causal gene (COL4A5).

7 Aug 2020

Researchers develop new therapeutic approach to treat CLN3 Batten disease

Researchers led by a team at Rosalind Franklin University of Medicine and Science have devised a new therapeutic approach to treating a rare but deadly neurodegenerative genetic disease in children.

31 Jul 2020

Neurotransmitter-derived lipidoids help carry drugs across the blood-brain barrier in mice

Biomedical engineers at the Tufts University School of Engineering have developed tiny lipid-based nanoparticles that incorporate neurotranmitters to help carry drugs, large molecules, and even gene editing proteins across the blood-brain barrier and into the brain in mice.

24 Jul 2020

Study: L-Grb2 has therapeutic efficacy in preclinical models of ovarian and uterine cancer

The cover for issue 29 of Oncotarget features, "In vivo effects of treatment with L-Grb2 in combination with anti-angiogenic therapy in an ovarian tumor model," by Lara, et al. which reported that adaptor proteins such as growth factor receptor-bound protein-2 play important roles in cancer cell signaling.

23 Jul 2020